Brief: Vaxcyte Advances Adult And Infant Programs For Vax-31, A Potential Best-In-Class, Next-Generation Pneumococcal Conjugate Vaccine
22/01/2026 22:36
Jan 22 (Reuters) - Vaxcyte Inc PCVX.O: VAXCYTE ADVANCES ADULT AND INFANT PROGRAMS FOR VAX-31, A POTENTIAL BEST-IN-CLASS, NEXT-GENERATION PNEUMOCOCCAL CONJUGATE VACCINE VAXCYTE: VAX-31 ADULT PHASE 3 NONINFERIORITY TRIAL (OPUS-1) CONTINUES TO ENROLL SUBJECTS, WITH TOPLINE DATA EXPECTED IN FOURTH QUARTER OF 2026 VAXCYTE: EXPECTS TO REPORT TOPLINE SAFETY, TOLERABILITY AND IMMUNOGENICITY DATA FROM BOTH OPUS-2 AND OPUS-3 PHASE 3 STUDIES IN FIRST HALF OF 2027 Source text: ID:nGNX5vDqlf Further company coverage: PCVX.O ((Reuters.Briefs@thomsonreuters.com;))